eligibility_summary
Inclusion: Adults 18–75 with advanced/metastatic NSCLC, ECOG 0–1, ≥12‑wk survival, adequate marrow/liver/renal/cardiac function (QTc≤450), EGFR‑sens mutation (incl ex20ins), prior EGFR‑TKI progression, MET IHC 1–3+, measurable disease, samples for T790M/PD‑L1, contraception. Exclusion: recent trials/surgery/vaccines, thrombosis, QT/arrhythmia, ILD/effusions, uncontrolled disease/infection (TB/HIV/HBV/HCV), CYP3A4 strong mod, pregnancy, SCLC, active brain/leptomeningeal mets (stable brain mets allowed), prior HGF/MET, recent therapy, unresolved ≥G2 toxicity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests RC108 + furmonertinib (alflutinib) ± toripalimab in advanced EGFR‑mutated, MET‑expressing NSCLC after EGFR‑TKI failure. Drugs/mechanisms: • RC108: a MET‑targeting antibody (reported as an antibody‑drug conjugate) designed to bind MET on tumor cells, inhibit HGF/MET signaling and deliver cytotoxic activity to MET‑positive cells. • Furmonertinib: small‑molecule, third‑generation, irreversible EGFR tyrosine kinase inhibitor selective for mutant EGFR (incl. T790M), blocking EGFR signaling. • Toripalimab: humanized IgG4 anti‑PD‑1 monoclonal antibody that releases T‑cell activity by blocking PD‑1/PD‑L1. Targets/pathways: EGFR‑mutant tumor cells (EGFR pathway), MET‑overexpressing/amplified tumor cells (HGF/MET pathway), and PD‑1 on T cells (immune checkpoint) to counter resistance and enhance antitumor immunity.